Femasys Inc (FEMY) — Titan Protect Analysis

FEMY

Femasys Inc

Healthcare · ·

$6.10

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$22M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.23

Based on estimated future earnings — lower means cheaper

Rev Growth

+39.9%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-455.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.00

+64% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About Femasys Inc

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual b

https://femasys.com

Country: United States Employees: 51 Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.036

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0563

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.537

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-43.5%

Historical annualised return based on price data

Max Drawdown

-81.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-2.26

Very low correlation to market moves

52W High

$1.11

-449% below the year high

52W Low

$0.31

1886% above the year low

Avg Volume

1,009,422

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.24

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

80.03

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

62.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-568.3%

Profit from core operations before interest and tax

Free Cash Flow

$-11,906,741

Negative — the business is spending more than it generates

Revenue (TTM)

$2M

Total revenue over the last 12 months

Net Income

$-18,627,888

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$12.00

Target Median

$10.00

Target Low

$3.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go